Mifamurtide (TFA)

Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide TFA has potential for use in rare disease and osteosarcoma research[1][2][3].

Product Specifications

Product Name Alternative

MTP-PE (TFA) ; L-MTP-PE (TFA) ; CGP 19835 (TFA)

UNSPSC

12352211

Target

NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mifamurtide-tfa.html

Purity

98.0

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)=O)=O.OC(C(F)(F)F)=O

Molecular Formula

C61H110F3N6O21P

Molecular Weight

1351.52

References & Citations

[1]Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6 (3) :677-89.|[2]Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25 (5) :1063-1074.e3.|[3]Francesca Punzo, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020 Feb 18;11 (7) :687-698.